JoAnn V Pinkerton, James Simon, Nick Panay, Christian Seitz, Susanne Parke, Cecilia Caetano, Uwe Mellinger, Nazanin Haseli Mashhadi, Claudia Haberland, Gordana Atanackovic, Cornelia Holz, Guangping Mao, Marina Morrison, Sven Nisius, Matthias Schaefers, Lineke Zuurman
OBJECTIVE: Elinzanetant is a selective neurokinin-1,3 receptor antagonist in development for the treatment of vasomotor symptoms (VMS) associated with menopause. The pivotal, double-blind, randomized, placebo-controlled phase 3 studies Overall Assessment of efficacy and Safety of elinzanetant In patients with vasomotor Symptoms (OASIS) 1 and 2 will assess the efficacy and safety of elinzanetant in women with VMS. METHODS: The OASIS 1 and 2 pivotal studies are designed in accordance with regulatory guidance...
April 3, 2024: Menopause: the Journal of the North American Menopause Society